Eli Lilly (NYSE:LLY) is an Indianapolis-based company that is engaged in the discovery, development, and marketing of human pharmaceuticals around the world. Shares of Eli Lilly have climbed 18% month-over-month as of close on Tuesday, August 27, 2024. Meanwhile, the stock has surged 61% in the year-to-date period.
The company has grown into one of the most sought-after US stocks due to the role it has played in the development, manufacturing, and marketing of the revolutionary GLP-1 class of drugs. These drugs, originally manufactured to treat Type-2 diabetes, have been found to have unprecedented weight-loss results. Ozempic is the popular brand introduced by Novo Nordisk, while Zepbound is Eli Lilly’s.
On August 27, Eli Lilly unveiled a new form of Zepbound. This Zepbound variant will be available for approximately half its usual monthly list price. This is designed to increase access for patients without insurance coverage. Moreover, the move aims to expand the U.S. supply of Zepbound in the midst of surging demand. That ensures that patients are able to safely access the treatment as cheaper copycat versions are increasingly gaining popularity.
These variants will be available in 2.5 milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month, respectively. That is through its direct-to-consumer website. Shares of Eli Lilly stock are still trading in solid value territory compared to its industry peers.
